These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 11264457)

  • 21. Neuroactive steroids in schizophrenia.
    Shulman Y; Tibbo PG
    Can J Psychiatry; 2005 Oct; 50(11):695-702. PubMed ID: 16363462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurotransmitters and CNS disease. Schizophrenia.
    Snyder SH
    Lancet; 1982 Oct; 2(8305):970-4. PubMed ID: 6127468
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation.
    Fitsanakis VA; Au C; Erikson KM; Aschner M
    Neurochem Int; 2006; 48(6-7):426-33. PubMed ID: 16513220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 25. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
    Kondziella D; Brenner E; Eyjolfsson EM; Sonnewald U
    Neurochem Int; 2007 Jan; 50(2):291-301. PubMed ID: 17084946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.
    Winterer G
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S68-71. PubMed ID: 16508900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
    Fitzgerald PB
    Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia.
    Cai HL; Zhu RH; Li HD; Zhang XH; Hu L; Yang W; Ye HS
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1273-8. PubMed ID: 20637820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interaction of neurotransmitters in specific circuits of the brain].
    Mora Teruel F
    An R Acad Nac Med (Madr); 1998; 115(3):653-7; discussion 657-8. PubMed ID: 10208018
    [No Abstract]   [Full Text] [Related]  

  • 31. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders.
    Wierońska JM; Pilc A
    Pharmacol Ther; 2019 Jan; 193():75-82. PubMed ID: 30149102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurotransmitter interactions in schizophrenia--therapeutic implications.
    Carlsson A; Waters N; Carlsson ML
    Biol Psychiatry; 1999 Nov; 46(10):1388-95. PubMed ID: 10578453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Brain of patients with chronic schizophrenia and neurotransmitters].
    Toru M
    Seishin Shinkeigaku Zasshi; 2005; 107(10):1015-21. PubMed ID: 16381382
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent advances in atypical antipsychotics.
    Armer R; Miller DJ
    Curr Opin Investig Drugs; 2000 Dec; 1(4):481-93. PubMed ID: 11249703
    [No Abstract]   [Full Text] [Related]  

  • 36. Phenotype of schizophrenia: a review and formulation.
    Tamminga CA; Holcomb HH
    Mol Psychiatry; 2005 Jan; 10(1):27-39. PubMed ID: 15340352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A glutamatergic deficiency model of schizophrenia.
    Carlsson A; Hansson LO; Waters N; Carlsson ML
    Br J Psychiatry Suppl; 1999; (37):2-6. PubMed ID: 10211132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor.
    Leriche L; Diaz J; Sokoloff P
    Neurotox Res; 2004; 6(1):63-71. PubMed ID: 15184107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
    Harrison PJ
    Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
    [No Abstract]   [Full Text] [Related]  

  • 40. GABA and schizophrenia: a review of basic science and clinical studies.
    Wassef A; Baker J; Kochan LD
    J Clin Psychopharmacol; 2003 Dec; 23(6):601-40. PubMed ID: 14624191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.